Background {#Sec1}
==========

Parkinson disease (PD) is an age-related neurodegenerative disorder, with a prevalence of 1--2% among adults aged 55 years and older \[[@CR1]\]. It is characterized by a progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta that results in tremor, rigidity, bradykinesia, and possibly dementia \[[@CR2]\]. The current evidence related to the pathogenesis of PD includes defective handling of proteins, mitochondrial dysfunction, oxidative stress, and inflammation \[[@CR3]--[@CR6]\]. There is no cure for the disease and only symptomatic relief is available. Especially in the early stages of the disease, dopamine replacement therapies provide effective control of the motor symptoms with L-dopa as the gold standard. However, chronic L-dopa use does not adequately manage the non-motor deficits and additionally induces a variety of motor and psychiatric side effects that limits its effectiveness \[[@CR7], [@CR8]\]. These shortcomings strengthen the importance of identifying alternate treatment strategies that delay or halt disease progression, or ideally restore function in PD. Previous reviews reported the association between nicotine and PD risk, but the sources were limited to cigarette smoking and medical use. We thus updated epidemiological, preclinical and clinical data, and studies on nicotine from other sources. We also reviewed interactions between genetic factors and cigarette smoking to broaden the understanding of the potential protective role of nicotine on PD.

Tobacco and PD {#Sec2}
--------------

Previous epidemiologic studies have consistently shown that cigarette smoking \[[@CR9]--[@CR12]\] and smokeless tobacco use \[[@CR13], [@CR14]\] are associated with a lower risk of PD. Environmental tobacco smoke exposure is also associated with a significantly lower PD risk among never active smokers \[[@CR15], [@CR16]\]. Population-based studies have shown that smoking was associated with approximately 40--50% reduced risk of developing PD. \[[@CR10], [@CR11]\] This inverse relationship between smoking and PD was dose-dependent: age-adjusted relative risks (RRs) of PD were 0.8, 0.6, 0.5, and 0.4, for 1-9, 10-24, 25-44, and 45+ pack-years, relative to never-smokers, as shown in a large prospective cohort study \[[@CR9]\]. There is also a temporal relationship between cigarette smoking and PD risk \[[@CR9], [@CR17]\]. Individuals with more years of smoking, older age at quitting smoking, and fewer years since quitting smoking had lower PD risk. Researchers prospectively observed a significantly lower risk of PD for smoking as early as 15 to 24 years before symptom onset, but not for smoking 25+ years before onset (*n* = 143,325) \[[@CR17]\].

For smokeless tobacco use, such as tobacco chewing and snus use, three epidemiology studies have investigated their association with PD. \[[@CR13], [@CR14]\] One case-control study with 196 cases, have shown that tobacco use, including tobacco chewing or snuff use, is inversely associated with risk of PD. \[[@CR13]\] In a cohort study with 9 years of follow-up, men who were current users of smokeless tobacco at enrollment had a significant lower risk of PD mortality (age-adjusted RR = 0.22, 95% confidence interval (CI), 0.07 to 0.67) \[[@CR14]\]. Another prospective cohort study with 307 PD cases also had a similar inverse association between snus use and PD in men \[[@CR18]\]. Consistently, in a case-control study based on 154 PD cases from Washington State, environmental tobacco smoke exposure was associated with 64% lower risk of PD. \[[@CR15]\] Among persons with passive smoking as the only tobacco smoke exposure, risk was inversely associated with years exposed \[[@CR15]\]. One cohort study using parental smoking as the tobacco exposure, has also shown the dose-response inverse association with PD incidence \[[@CR16]\].

Because smoke has always been shown as a cause of adverse health outcomes, the inverse association between smoking and the risk of PD was counterintuitive. Some researchers believed that this relation resulted from a true biological protective effect of cigarette smoking. However, some researchers proposed that the reverse association might result from bias. For example, the association between smoking and lower PD risk could be explained by a still-unknown third factor that increases the risk of PD and also causes an aversion to smoking behavior \[[@CR19]\]. A recent study reported that patients with PD were able to quit smoking more easily than controls \[[@CR19]\]. This study suggests that the ease of smoking cessation is an early manifestation of pre-motor PD related to the loss of nicotinic rewards. In this case, quitting smoking could be just a pre-clinical marker rather than a risk factor \[[@CR20]\]. However, in a case-control study in France, with 247 cases and 676 controls, when smoking was defined as cigarette smoking 18 years before PD onset, the same inverse association was still present \[[@CR21]\].

Further, one of disadvantages of case-control studies is incidence-prevalence bias. This type of bias could be due to higher smoking-related mortality among incident cases than among controls, leading to a lower proportion of smokers among prevalent PD cases than among controls. However, the results of prospective cohort studies are in agreement with the results of case-control studies, which could minimize this type of bias. In addition, in a prospective study in the Health Professional Follow-up Study with 288 incident PD cases, smoking was not associated with a higher relative risk of death among PD patients than among non-PD patients \[[@CR22]\]. An alternative hypothesis that genetic polymorphisms that influence tolerance to tobacco smoke may also increase the risk of PD might account this inverse association. Twin studies are usually used to test this type of hypothesis as a gold standard. An inverse relationship between smoking and PD was observed among monozygotic twins, suggesting that genetic factors is unlikely to confound this relationship \[[@CR23], [@CR24]\].

Smoking and prodromal PD {#Sec3}
------------------------

REM sleep behavior disorder (RBD) is a parasomnia characterized by symptoms of dream-enacting behaviors and a loss of muscle atonia throughout a REM period as confirmed by polysomnography \[[@CR25], [@CR26]\]. A large proportion of individuals (\>75%) with RBD developed neurodegenerative synucleinopathy based on prospective cohort studies \[[@CR27]--[@CR31]\]. However, in a hospital-based case-control study, RBD cases were more likely to smoke (adjusted OR = 1.43, *p* = 0.028), although nonsmoking status has been consistently linked with risk of PD. \[[@CR32]\] In addition, two recent community-based cross-sectional studies \[[@CR33], [@CR34]\] showed that smoking was not a significant risk factor for probable RBD. For example, in our previous study based on 12,784 Chinese participants of the Kailuan study, the adjusted ORs for probable RBD was 0.91(95% CI: 0.74-1.1) for current smoking and 1.17 (95% CI: 0.85--1.6) for past smoking, compared with non-smokers \[[@CR33]\]. In this context, it is possible that some RBD have different pathogenesis.

Both population-based studies \[[@CR35], [@CR36]\] and those performed in at-risk populations \[[@CR37]--[@CR40]\] showed that impaired olfactory function was associated with higher PD risk, and could predate development of PD \[[@CR35]\]. With regard to the association between smoking and olfactory function, previous studies (all cross-sectional design) generated mixed results: some \[[@CR41], [@CR42]\], but not all \[[@CR43]--[@CR47]\], reported that smokers were more likely to have olfactory dysfunction. It remains unclear whether this is due to a true biological effect of smoking on olfaction or a reverse causality -- individuals with olfactory dysfunction may quit smoking.

Constipation and higher risk of developing PD was observed in six population-based studies \[[@CR48]--[@CR53]\]. A cross-sectional study with 516 functional constipation cases reported an association between smoking and higher likelihoods of several functional gastrointestinal symptoms, including functional constipation \[[@CR54]\]. Researchers observed that smoking delayed gastric emptying of solids, rather than liquids, and nicotine was not responsible for the effect \[[@CR55]\], while acute cigarette smoking in habitual smokers delayed mouth--cecum transit time, an effect most likely due to nicotine \[[@CR56]\]. After use of transdermal nicotine application in nonsmokers, a dose-dependent, significant decrease of total colon transit time was observed, mainly due to an accelerated transit in colon sigmoideum and rectum \[[@CR57]\]. Additionally, colonic transit time was significantly shorter in men than in women, and smoking males have prolonged colonic transit time compared with nonsmoking men, while a difference was not observed in women \[[@CR58]\]. However, in another cross-sectional study with 148 functional constipation cases in Bangladesh, smoking was not associated with functional constipation \[[@CR59]\].

Regarding another risk factor for prodromal PD -- erectile dysfunction \[[@CR53], [@CR60]\], multiple human, animal, case series, cross-sectional, and cohort studies support the notion that cigarette smoking is a risk factor for erectile dysfunction. Further, a positive dose-response relation has also suggested that increased quantity and duration of smoking is associated with a higher risk of erectile dysfunction \[[@CR61]\].

Mechanism of nicotine and PD {#Sec4}
----------------------------

Findings on the inverse association between cigarette smoking and PD, together with observations that smokeless tobacco users had a lower risk of PD \[[@CR14]\], support the notion that certain tobacco components, possibly nicotine, could be a promising substance for preventing against PD risk or slowing PD progression \[[@CR62]\].

The rationale for the candidate role of nicotine is on the basis of evidence demonstrating a close anatomical relationship between the nicotinic cholinergic and dopaminergic neurotransmitter systems in the striatum \[[@CR63]\]. Nicotine and its receptors play a key role in regulating striatal activity and behaviors mediated through the dopaminergic system \[[@CR64]\], by activation of nicotinic acetylcholine receptors (nAChRs) on dopaminergic terminals and modulating dopamine release \[[@CR65]--[@CR67]\]. In experimental neuroscience, nicotine has shown beneficial effects \-- nicotine or its agonists protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced striatal damage and improve motor function in animal models of PD. \[[@CR62], [@CR64], [@CR68]--[@CR73]\] Nicotine and its agonists could also reduce levodopa-induced dyskinesias (LIDs) and had been evaluated in rodents and monkeys. In Parkinsonian monkeys, administration of nicotine reduced LIDs by 50--60%, without development of tolerance \[[@CR74]--[@CR77]\]. With respect to hemiparkinsonian rats, which received levodopa injection, nicotine also reduced dyskinesia by more than 50% \[[@CR78], [@CR79]\]. In vivo studies, researchers found that nicotine significantly reduced plasma levodopa concentration, and also observed that nicotine inhibited levodopa transport by Caco-2 cell monolayers in a manner of α-methyl amino isobutyric acid-independence and 2-amino-norbornanecarboxylic acid-dependence in vitro studies \[[@CR80]\]. These results yield insight that nicotine may inhibit the transport of levodopa by the system L-amino acid transporter.

Regarding mechanism of neuroprotection against PD, another hypothesis states that the elevation of brain Cytochrome P450 enzymes (CYPs) induced by nicotine may play a role \[[@CR81]\]. According to this hypothesis, higher levels of CYP enzymes in the brain, whether due to genotype or CYP induction by nicotine, can increase inactivation of neurotoxins, thus delaying development and progression of PD. \[[@CR81]\] In addition, a novel hypothesis recently proposed that cigarettes may change the composition of the microbiota in the gut in a manner of mitigating intestinal inflammation \[[@CR82]\]. Upregulation of anti-inflammation by nicotine would in turn lead to less misfolding of the protein alpha-synuclein, a substance inducing neurodegeneration in enteric nerves, thus minimizing propagation of the protein aggregates to the central nervous system \[[@CR82]\].

Dietary nicotine and PD {#Sec5}
-----------------------

As demonstrated by a neuro-image study, a substantial portion of nicotine receptors became occupied when exposed to relatively small amount of nicotine \[[@CR83]\]. This notion has further been supported by the observation that long-term smoking is more important than smoking intensity in the smoking-PD relationship \[[@CR84], [@CR85]\]. Besides cigarettes, nicotine has a wide distribution in flora and presents in some common vegetables that belong to the biological family of nightshades. They include potatoes, tomatoes, and peppers. Of note, the intake amount from these vegetables is generally much lower relative to that obtained from tobacco.

In a recent case-control study including 241 PD cases, each additional serving of edible solanaceae was associated with 31% lower risk of PD among never-smokers (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR86]\]. However, due to its retrospective design, possibility of reverse causality cannot be excluded, and some PD symptoms (e.g., olfactory dysfunction and difficulty swallowing) might change eating habits.Fig. 1Parkinson disease risk associated with each additional serving of edible Solanaceaea and other vegetables \[[@CR86]\]. ^a^ Among never-used-tobacco participants (241 PD cases and 239 controls) in a case-control study in western Washington State.^b^ All assessed edible Solanaceae: green, yellow or red peppers, tomatoes, tomato juice, and baked or mashed potatoes. ^e^ Relative risk (odds ratio) and 95% confidence interval, per once daily increase in typical adult life frequency of consumption, adjusted for age (continuous), sex, race/ethnicity, consumption of other vegetables (continuous) and caffeine (mg, continuous); and adjustment for or stratification by tobacco use (ever vs. never \>100 cigarettes or regularly used cigars, pipes or smokeless tobacco). ^d^ All assessed non-Solanaceae vegetables combined: broccoli, cauliflower, cabbage, Brussels sprouts, radishes, lettuce, spinach/other greens, carrots, peas/lima beans, corn, sweet potatoes/yams, cucumbers, zucchini, yellow/winter squash and onions/scallions. ^c^ Median dry-weight nicotine concentration in each Solanaceae as typically consumed (e.g. ripe tomatoes and cooked potatoes) \[[@CR116]\]

Clinical trials {#Sec6}
---------------

It is worth noting that unlike caffeine \[[@CR87]\], urate \[[@CR88]--[@CR90]\] and flavonoids \[[@CR91]\], which appear to be associated with lower risk of PD in only men but not in women, a strong inverse relationship between smoking and PD risk has been consistently observed in both men and women across populations. This relationship suggests that nicotine or other compounds in tobacco could be an excellent therapeutic agent.

Clinical trials and case studies regarding nicotine treatment have generated mixed results \[[@CR62], [@CR68], [@CR92]\]. In addition to some benefits observed in case reports \[[@CR93], [@CR94]\], open-label studies yield mostly positive results \[[@CR95]--[@CR101]\], except for one of the eight open-label studies with no effect \[[@CR102]\]. For those double-blinded placebo-controlled trials, three out of five reported no effect \[[@CR103]--[@CR105]\], while one showed worsening results \[[@CR106]\] and one manifested positive results \[[@CR107]\]. These studies are small (\<80 PD cases) and such controversies may lie in discrepancies in the clinical stages of PD participants, administration of nicotine, and dosage and duration of nicotine treatment. Particularly, it is too late to do intervention by the time of clinical diagnosis of PD, which is at the late stage of the disease progression with irreversible impaired nervous system. Therefore, any intervention at this time might only have limited effects. In addition to those studies, recently three clinical trials are ongoing to the best of our knowledge. An open pilot study suggested that transdermal nicotine may improve motor scores and slow degeneration of dopaminergic neuron terminals \[[@CR100]\]. The corresponding follow-up study with 40 PD patients ([ClinicalTrials.gov](http://clinicaltrials.gov) ID NCT00873392) is complete, but published results are not presently available. Another study with 65 PD patients where an oral capsule of nicotine was given instead of a transdermal patch was completed, but to date no data have been published ([NCT00957918](https://clinicaltrials.gov/ct2/show/NCT00957918)). The third clinical trial is currently in progress to test whether transdermal nicotine can slow progression in early PD among 160 PD patients ([http://clinicaltrials.gov](https://clinicaltrials.gov/ct2/show/NCT01560754) identifier).

Further, some early small clinical trials reported poor tolerability of transdermal nicotine. For example, in a trial including 24 nonsmoking PD patients who received a transdermal nicotine treatment over 25 days, 14 participants had side effects such as nausea, vomiting, and dizziness, and 10 of them withdrew from the study \[[@CR108]\]. These possible adverse effects highlight the importance of understanding the potential effect of low-dose nicotine obtained from other sources, such as edible solanaceae foods.

Smoking-related gene and PD {#Sec7}
---------------------------

Except positing that nicotine is neuroprotective, inherent aversion to nicotine-containing products could be another potential explanation. To date, several genetic studies have been conducted to explore the potential interaction between smoking and genetic factors on PD risk (Table [1](#Tab1){ref-type="table"}). For example, a study including 677 PD patients reported a significant interaction between the nicotinic cholinergic receptor gene cluster CHRNA5 (rs588765) and smoking on age of onset of PD. \[[@CR109]\] In an early study that included 466 singletons and 286 multiplex families, significant interactions between smoking and two SNPs (rs2255929 and rs1060826) of inducible nitric oxide synthase (iNOS) gene (NOS2A) in relation to PD risk were observed \[[@CR110]\]. One possible interpretation for this observed interaction is that cigarette smoking condensates could attenuate inflammatory induction of iNOS, and reduce its cytotoxic effects \[[@CR110]\].Table 1Gene-smoking interactions for Parkinson DiseaseFirst author, year of publicationStudy participantsGene studiedResultsGreenbaum, 2013 \[[@CR109]\]667 Italian PD patientsCHRNA3, CHRNA4, and CHRNA5A significant interaction between the CHRNA5 (rs588765) and smoking status (never smokers vs. ever-smokers)Hancock, 2006 \[[@CR110]\]466 singleton and 286 multiplex families in the United StatesNOS2ASignificant interactions of NOS2A (rs2255929 and rs1060826) with smoking in a subset of the familiesMiyake, 2012 \[[@CR113]\]229 PD patients and 357 controls in JapanSNCASignificant interactions between SNCA (rs356219 and rs356220) and smoking with respect to sporadic PDMcCulloch, 2008 \[[@CR112]\]932 PD patients and 664 controls in the United StatesMAPT, SNCA, UCHL1, and APOEA significant interaction between SNCA REP1 and smokingGao, 2012 \[[@CR91], [@CR114]\]584 PD patients and 1571 controls (non-Hispanic Caucasians)SNCA, MAPT, SLC2A13, and HLAA significant interaction with rs2896905 at SLC2A13Palma, 2010 \[[@CR115]\]767 PD patients and 1989 controls in EuropeCYP1B1, CYP2D6, GSTM1, GSTM3, GSTT1, GSTP1, NQ01, SOD2, EPHX, NAT2, MAOA, MAOB, DAT1, and DRD2Significant interactions between smoking and GSTM1 Pos/Null, GSTP1 haplotype, and NAT2 Fast/slow

Although earlier results were inconsistent, recent studies showed that a dinucleotide repeat polymorphism (REP1) in the promoter region of the α-synuclein gene (SNCA) was associated with the risk of common late-onset PD. \[[@CR111]\] For example, a case-control study with 932 PD cases showed an interaction between SNCA REP1 and smoking on the risk of PD. \[[@CR112]\] Another recent case-control study including 229 PD cases reported that smoking significantly modified the association between SNCA polymorphisms (rs356220 and rs356219) and PD risk \[[@CR113]\]. In addition, many other genetic polymorphisms have been implicated in tobacco-PD relation, such as SLC2A13, GSTM1, NAT2, and GSTP1, etc., but the findings are inconsistent \[[@CR114], [@CR115]\].

Conclusions {#Sec8}
===========

Despite of extensive evidence from epidemiological and basic research studies suggesting that nicotine may represent an effective agent with potential for prevention and alleviation PD, clinical data vary to a major extent between individuals. Discrepancies of those controversial results can be partly explained by differences of clinical stages of PD participants and research methodologies, and may also be due to the underlying gene-environment interactions. In addition, poor tolerability and high drop-out rate are inevitable concerns in such clinical trials. As a small amount of nicotine can saturate a substantial portion of nicotine receptors in the brain, nicotine from other sources, such as diet, could be a promising therapeutic substance for protection against PD.
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